Anavex Life Sciences Corp.
OTC Bulletin Board : AVXL

Anavex Life Sciences Corp.

April 02, 2007 11:48 ET

Anavex Life Sciences Corp. Announces Research Agreement With University of Paris 5-Rene Descartes

GENEVA, SWITZERLAND--(CCNMatthews - April 2, 2007) - Anavex Life Sciences Corp. (the "Company") (OTCBB:AVXL), a biopharmaceutical company, announced today that it has entered into a research agreement with the department of Pharmacology and Biological Sciences at Paris 5 University-Rene Descartes, France, to investigate the neuroprotective action of Anavex's tetrahydrofuranic compound ANAVEX 19-144 (AE37Met) in transient focal cerebral ischemia animal models. With this new agreement, Anavex Life Sciences Corp. partners with one of France's leading research universities. The research program involves two parts, a preliminary study of the effects of ANAVEX 19-144 on mean arterial blood pressure and a main study on cerebral ischemia.

Dr. Panos Kontzalis, PhD, CEO at Anavex Life Sciences Corp., commented, "This research agreement with the University of Paris 5 represents a valuable addition to our expanding portfolio surrounding the family of sigma receptors and broadens our ability to fully explore the potential of Anavex's novel sigma receptor ligands in the therapeutic field of cerebral ischemia."

About ANAVEX 19-144 (AE37Met)

ANAVEX 19-144 is a new tetrahydrofuranic compound in advanced preclinical phase for the treatment of epilepsy as monotherapy or as adjunct therapy to existing drugs. ANAVEX 19-144, presents mixed pharmacological activity involving muscarinic, sodium channel, NMDA and sigma-1 components showing prominent anti-amnesic, anticonvulsive and anti-depressant potential. The drug acts as simultaneous antagonist on presynaptic M2 autoreceptors and on the presynaptic M3 muscarinic heteroreceptors of the glutamatergic neuronal endings, in synergy with its agonism on the intracellular sigma-1 receptor mainly located on the endoplasmic reticulum concerning the first (anti-amnesic) activity and, at higher doses (5 - 50 mg/kg per os or ip) as antagonist on sodium and calcium channels, weak antagonist of NMDA receptors, concerning the anticonvulsive and antidepressant activity.

About Anavex

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases utilizing a fairly new class of receptors, (sigma receptors), involved in the modulation of multiple cellular biochemical signaling pathways.

Legal Notice regarding Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to ANAVEX 19-144 and the potential of this compound as treatment for neurological diseases and/or cerebral ischemia and the effectiveness and efficiency of the Anavex technology to generate novel lead molecules for therapeutic targets. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file an IND or commence clinical studies in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its development candidates will have favorable results in preclinical studies or future clinical trials. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Contact Information

  • Anavex Life Sciences Corp.
    Harvey Lalach
    President
    (250) 764-9701
    Email: harvey@anavex.com